



HAL
open science

Leptomeningeal spread in glioblastoma: diagnostic and therapeutic challenges

Cristina Birzu, Suzanne Tran, Franck Bielle, Mehdi Touat, Karima Mokhtari, Nadia Younan, Dimitri Psimaras, Khe Hoang-xuan, Marc Sanson, Jean-yves Delattre, et al.

► To cite this version:

Cristina Birzu, Suzanne Tran, Franck Bielle, Mehdi Touat, Karima Mokhtari, et al.. Leptomeningeal spread in glioblastoma: diagnostic and therapeutic challenges. *Oncologist*, 2020, 25 (11), 10.1634/theoncologist.2020-0258 . hal-03268752

HAL Id: hal-03268752

<https://hal.sorbonne-universite.fr/hal-03268752v1>

Submitted on 23 Jun 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Leptomeningeal spread in glioblastoma: diagnostic and therapeutic challenges

Birzu C¹, Tran S², Bielle F², Touat M¹, Mokhtari K², Younan N¹, Psimaras D¹, Hoang-Xuan K¹, Sanson M¹, Delattre JY¹, Idbaih A¹

1. Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, F-75013, Paris, France

2. Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neuropathologie-Escourolle, F-75013, Paris, France

The research leading to these results has received funding from the program Investissements d'avenir" ANR-10-IAIHU-06.

Institut Universitaire de Cancérologie¹

INCA-DGOS-Inserm_12560 SiRIC CURAMUS is financially supported by the French National Cancer Institute, the French Ministry of Solidarity and Health and Inserm.

Introduction

Glioblastoma (GBM) is the most common and the most aggressive primary malignant brain tumor in adults.¹⁻³ Its annual incidence is close to 3 per 100,000 habitants per year. The treatment of newly diagnosed GBM patients relies on maximal safe surgical resection followed by radiotherapy with concurrent and adjuvant temozolomide chemotherapy⁴. Despite the intensive therapeutic regimen, the prognosis of GBM patients remains poor with a median overall survival below 18 months and a five-year survival rate of 5.6%².

The propensity of GBM to metastasize to cerebrospinal fluid (CSF) flow stream inducing GBM leptomeningeal spread (LMS) was firstly described in 1931⁵. LMS results from spreading of tumor cells from brain parenchyma to leptomeninges and CSF and is one of the most severe complications of GBM. Other severe complications of GBM include: (i) intratumor hemorrhage, (ii) status epilepticus and, (iii) hydrocephalus. As the prognosis of GBM patients improves, LMS becomes a more frequent clinical issue in neuro-oncology^{1,6,7}.

Considered initially as a rare complication in gliomas,⁸ the incidence of LMS seems above the estimated rate of 4% reaching 25% on postmortem neuropathological studies^{1,5,6,9,10}. In case of LMS, the median overall survival of GBM patients varies between 2-5 months^{1,6,7,11,12}. No risk factor has been clearly demonstrated although multiple factors have been suggested: (i) age, (ii) histologic features, (iii) molecular alterations, (iv) anatomical tumor site and, (iv) therapeutic interventions (*e.g.* surgical opening of the ventricles or antiangiogenic therapies)^{1,6,13-16}.

Diagnosis of LMS in GBM patients is challenging. The sensitivity of classical diagnostic investigations (*i.e.* MRI and cytological CSF analysis) remains low, failing identification of tumor CSF spread most of the time^{17,18}.

There is no standard of care treatment for LMS in GBM patients even though multiple groups have proposed several therapeutic options (*e.g.* methotrexate, cytarabine, thiotepa and/or, ACNU) with limited efficacy so far.^{1,6,7,11,15,19-21} Interestingly, the treatment with intrathecal chimeric antigen receptor T cells has demonstrated dramatic efficacy in a single patient²². The uprising molecular targeted therapies and immunotherapies supports further exploration of the molecular landscape of CSF circulating GBM cells²³⁻²⁶.

Diagnostic and therapeutic challenges raised by LMS in GBM patients will be presented and discussed in the current review.

Method

We conducted a survey, from 01/01/1989 to 31/12/2019, in PubMed Database and Scopus-EMBASE using the following combination of terms connected by Boolean operators: (glioma OR high grade glioma OR glioblastoma) AND (meningeal OR leptomeningeal OR leptomeningeal dissemination OR meningeal gliomatosis OR leptomeningeal gliomatosis OR meningeal metastasis OR CSF dissemination) to identify relevant studies related to LMS and glioma.

Our search retrieved 2043 articles. We have excluded: (i) duplicate articles, (ii) articles in other language than English and French and, (iii) irrelevant articles –*i.e.* primary meningeal

gliomatosis, pediatric tumors. Eighty-five full text articles were selected. Based on this first selection and linked-list of references, additional articles were identified and included in our review. Overall, 156 articles were identified as relevant to the topic. The research algorithm is schematized in Figure 1.

Epidemiology

LMS in high-grade gliomas was reported by several authors (Table 1). In a series of 600 GBM, Vertosick et al estimated the incidence rate of symptomatic LMS at 2%^{1,6,7,10,11,27-32}. This incidence rate is probably underestimated due to undiagnosed and asymptomatic cases. Indeed, in autopsy studies LMS was identified in up to 25% of high grade glioma patients^{1,10,15,27,28,33}.

Pathogenesis

Few is known about the pathogenesis of LMS. CSF dissemination seems to follow two patterns: (i) intense CSF seeding with limited tumor progression at initial tumor site or, (ii) minimal CSF seeding with massive tumor progression at initial location^{1,5,10,34}.

GBM cells migrate from the initial tumor site along brain vessels to subpial, subarachnoid and subependymal spaces (figure 2a)^{5,10,35,36}. The leptomeningeal seeding from cortical areas is preceded by subpial spread as an intermediary step^{5,10,17,35}. During this migratory process, GBM cells secrete multiple proteases degrading the extracellular matrix (ECM) (e.g. MMP 1, 2, 7, 9, 14, and 19 with a critical role of MMP 2 and 9) to create a moving space³⁷⁻⁴² and express multiple adhesion-migration proteins (e.g. glycosylated chondroitin sulfate proteoglycans, fibronectin, fascin and, integrins)^{35,39,41,43}. Both molecule classes, working synergistically with cytoskeleton, allow tumor cells migration toward leptomeninges and CSF^{5,18,28,30,35,39,41,43-45}.

Furthermore in a mouse model prolonged VEGF inhibition converted tumor cells phenotype to invasive/mesenchymal leading to tumor invasion through perivascular and subpial spaces⁴⁶. Multiple proteins including FGF, IGFBP2, MMP2, Podoplanin, Fascin, MET, TGF-B and, IL8 are involved in this process but further insight is needed^{44,46-50}.

The role of the glioma stem cell like cells and their cross talk with microenvironment cells in tumor cell migration remains poorly understood^{41,45}. Translational and preclinical research are shedding light on molecular and cellular mechanisms of this phenomenon and its implication in invasiveness potential of GBM and in LMS development^{26,37,51-53}.

Clinical presentation

Two thirds of GBM patients develop LMS within the two first years after diagnosis^{1,7,11,20,28,30,33,54}. The median delay from initial diagnosis of GBM to clinico-radiological evidences of LMS varies from 5 to 16.4 months^{1,5-7,10,11,15,20,28,30,33,55-58}. This delay is shorter in specific tumor location including pineal, spinal, periventricular and infratentorial^{12,15,59-66}.

Clinical presentation of LMS is heterogeneous, from asymptomatic to severely symptomatic disease^{1,6,11,12,15,29,31,67}. Usually the onset and the worsening of symptoms are progressive, acute presentation is exceptional^{5,12,27,36,68-70}.

LMS patients can suffer from cranial nerves palsies, increased intracranial pressure syndrome, hydrocephalus, meningism, and/or focal neurological deficits^{1,7,15,20,33,71-76}.

Seizures frequency does not seem to increase during LMS development⁷⁷. Confusion and generalized cognitive decline are the most common features of LMS in elderly GBM patients^{15,78,79}. Although rare, aseptic fever, central neurogenic hyperventilation and cardiac arrest are reported^{5,11,12,70,80}.

Intractable vomiting may be an early symptom of CSF seeding to the fourth ventricle⁸¹. Cranial nerves deficits including 2nd, 3th, 4th, 6th and/or 7th, are observed in 6 % of cases^{8,78}. The 4th and 7th are the most frequently involved^{78,82}. Once installed, cranial nerve palsies are often irreversible^{5,27}.

Progressive paraplegia,^{9,27,36,69,73,83,84} sphincters incontinence^{1,11,36,55,80,84} and spinal ataxia^{20,29,80} were described when the spinal cord or cauda equina are involved^{9,29,30,33,69,73,85,86}. Isolated symptoms such as paresthesia, ataxia, back pain and leg or shoulder pain are rare^{27,29,87,88}. Radicular pain has been described with various topography: the upper limbs, interscapular⁸⁹ thoracic or lumbar level as well as sciatalgia^{1,5,11,15,20,33,55,90}.

Noteworthy, although LMS may manifest as communicating hydrocephalus³³, only 25-40 % of LMS present this complication^{75,91}.

Risk factors

A number of risk factors of LMS have been investigated in GBM patients. Young age (around 35 to 45 years), brain location, male gender, long survival after initial diagnosis and tumor volume seem to be associated with a greater risk of LMS in GBM patients^{1,6,27,78}.

The initial tumor location seems to be of importance. Indeed, infratentorial location (in 45 % to 100 % of cases)^{1,5,10,13,62,63} and GBM of the pineal region⁵⁹ are associated with a higher frequency of LMS. The spatial proximity to ventricles and the tumor size were considered as risk factor of LMS but existing data are conflicting^{1,6,7,11}. Indeed, invasive behavior of tumor cells and the environment of the subventricular zone (SVZ) have been pinpointed^{1,14,15,30,85,92,93}.

Ventricular opening during surgery and repeated surgeries, even more in patients treated with radiotherapy or chemotherapy^{5,89} have been proposed as risk factors of LMS^{15,65,94,95}. However, none has been clearly validated^{1,14,29,75,92-97} and prophylactic radiotherapy in these cases does not bring supplementary benefit⁹⁸. Persistence of preoperative leptomeningeal enhancement after initial surgical resection was also correlated with a higher LMS incidence in recurrence⁹⁹.

Hydrocephalus with subsequent ependymal fissuring has also been suggested as a potential but not formally validated risk factor^{89,100}.

Histological and molecular characteristics of initial tumor were also investigated. Astrocytic phenotype, high Ki67/Mib1 expression index^{1,29,60,85,101,102} and GFAP loss of expression either at initial diagnosis¹⁰ or at recurrence^{28,29} were correlated with higher risk of LMS. Epithelioid GBM^{26,103,104} and GBM with a neuronal component or PNET-like GBM^{56,74} disseminate more frequently to CSF.

Some molecular alterations have been also suggested as risk factors of LMS⁸⁵. Gain of 1p36¹⁰⁵, *PTEN* mutation^{102,106} and *PIK3CA* mutations¹⁰⁷ seem to predispose to meningeal seeding^{102,105,106}. O6-methylguanine-DNA methyltransferase promoter methylation was also proposed as risk factor by isolated studies^{65,108}. The suspected mechanisms is increased survival in MGMT promoter methylation GBM patients giving time to tumor cells to reach

CSF⁶⁵. This was not confirmed by larger studies^{11,109} and up to date, no molecular signature has been validated as risk factor of LMS in high grade glioma.

Antiangiogenic therapies (VEGF and COX2 inhibitors) have been suggested as promoters of distant recurrence including LMS^{44,48} but available data are conflicting. Further studies are needed^{1,49,50,110}.

Diagnostic approach

Imaging

Currently, the standard exam for LMS diagnosis is contrast MRI with a sensitivity reported between 90% and 100% for brain^{1,6,11,99,111-114} and 56-95 % for spinal LMS in symptomatic patients^{1,6,11,114}. Radiological screening of the neuraxis is required in GBM patients with suspected LMS symptoms^{71,111,115}.

However, the benefit of neuraxis screening for GBM patients without LMS symptoms remains unclear. This could be considered since the presentation can be asymptomatic and LMS can occur with stable disease at initial tumor site particularly in subgroups of high risk of LMS^{1,29,56,59,63,103,111}. Exceptional cases of asymptomatic LMS like-leptomeningeal enhancement on MRI were reported in the setting of radio induced pseudo progression¹¹⁶.

Typically LMS appears on MRI as linear and/or nodular foci with high signal intensity on T2 weighted images, low signal intensity on T1 weighted images and enhanced after gadolinium injection¹¹¹. MRI LMS pattern was proposed using enhancement characteristics: (i) nodular -type Ia, fig. 4-, (ii) diffuse -Ib, fig. 5- in the subarachnoid space^{18,34} and, (iii) subependymal dissemination -type II fig. 4,6- is also described regardless CSF cytology status³⁴. Mixed pattern is also possible – figure 6^{1,34}. Distribution of LMS varies involving commonly the anterior parts of brain stem and cranial nerves¹⁰¹. Still, the expanded use of antiangiogenic agents seems to modify this pattern making it more difficult to distinguish, in these cases a potential interest of contrast enhanced FLAIR sequences can be discussed^{34,55}.

In intracranial LMS, brain MRI can show multiple aspects: (i) nodular enhancement 38% -subarachnoid or ventricular fig 4- and, (ii) pial enhancement 47 % -focal or diffuse-^{1,11,34}. Nerve roots enhancement can be seen in some cases (57%) as well as cranial nerve infiltration (11-19%)^{1,34,78}. Exceptional presentation mimicking chronic subdural hematoma or empyema have been reported^{117,118}.

Spinal LMS has been reported to be more frequently in lower thoracic, upper lumbar (most often posterior)^{36,101}, lumbosacral regions, cauda equina and dural sac³⁶. 31% of lesions are described on cervical level, 52 % on thoracic level and 41% at lumbar level (fig 2b).^{1,34,101,111} Cauda equina and conus medullaris were involved in up to 38% of cases^{1,111}.

Intraoperative detection of LMS using 5-aminolevulinic acid (5-ALA) was reported as useful in anaplastic astrocytoma (histone K27M mutated)⁹ but its benefit is inconsistent⁶⁶. Nuclear imaging detecting hyper metabolic foci using F-FDG^{22,23} or TSPO(translocator protein) with F-GE-180^{119,120} can be helpful.

CSF study

CSF analysis is often negative for detection of tumor cells, only 25-45% are positive after a first assay^{1,11,30,65}. Repeated lumbar puncture increases the diagnostic sensitivity to 86% with 3 consecutive lumbar punctures^{65,71,78} and to 93% with more than 3 lumbar

punctures⁶. Nevertheless, even in cases of radiologically confirmed LMS, CSF cytological results were positive in only 4–75% of cases making an abnormal neuropathological CSF study sufficient but not necessary for diagnosis of LMS in gliomas^{1,6,11,28,65,85}. Indirect aspects can be observed as high intracranial pressure (>15 cm H₂O), high proteins level (>50-100 mg/dL) with or without low glucose, high lactate with an acellular aspect^{15,85,121} although a mild pleocytosis with presence of macrophages has been described⁹⁴.

On cytological exam, GBM cells were noted most often to be singly dispersed in the CSF (fig 2c). The main challenge is their distinction from monocytes¹⁸.

The input of liquid biopsies in diagnosis and monitoring of LMS in GBM patients, has been explored with increasing interest over the last years^{122–124}. Collecting and analyzing tumor components floating in CSF (i.e. circulating tumor cells, CTCs; cell-free tumor DNA (ct DNA) RNAs, (ctRNA, miR and exosomes) may help noninvasive diagnosis of CNS tumors and heighten the sensitivity in LMS detection^{122,123,125}. CTCs and ctDNA seem to be of clinical interest¹²⁶. In systemic malignancies CSF CTC assay has a reported sensitivity between 81-100% and a specificity of 85-97%. However, for non-epithelial malignancies such as GBM, the appropriate detection technique needs to be established^{122,126}.

As for the CSF ctDNA, analysis can be particular useful for detection of clonal mutations (BRAF V600E, IDH1, IDH2, TERT promoter, ATRX and TP53 mutations, EGFR amplification,) ^{23,122,123,127}. Noteworthy, although there is a clear correlation between CSF ctDNA and survival, the CSF detection of ctDNA does not systematically mean LMS, its clinical value in this context remains to be established¹²².

Therapeutic approach

In most cases, LMS in glioma patients is considered an untreatable end stage complication of the disease³⁴. There is no consensus nor standard of care regarding treatments⁸¹. Multiple treatment modalities, such as intrathecal chemotherapeutics and radiation therapy, seem to have improved median survival from 4–6 weeks to 3–6 months in high grade gliomas¹²⁸ Survival of LMS GBM patients in studies is reported at 0.2-9.7 months with a mean of 4.7 months^{1,28,129}.

Progression of the disease or treatment related complications (as hemorrhage¹³⁰, infections^{20,33} after intrathecal administrated treatment or ventriculoperitoneal shunting^{20,131,132}) may sometimes contribute to the fatal outcome^{82,130}.

Surgery

Because of the multifocal character of LMS, surgical approach is not suitable⁸⁷. Surgical resection of compressive nodular focal leptomeningeal lesions may provide symptomatic benefit without impacting survival^{9,68,83}. Another use for surgery in LMS is placement of a ventriculo-peritoneal (VP) shunt in case of hydrocephalus^{11,14,20,72,131,133}. This seems to be necessary in up 20-30% of patients¹¹. The main complications are shunt occlusion due to high fibrinogen CSF concentration^{132,134}, VP valve malfunction¹³⁴, hemorrhage, meningitis^{20,131,134} as well as extracranial dissemination in peritoneal cavity^{111,134}. The latter is exceedingly rare, although postmortem diagnosis in asymptomatic patients is possible^{111,134}. In case of shunt occlusion, the use of urokinase can be considered¹³² and careful monitoring should be ensured^{20,131}.

Radiotherapy

Palliative radiation therapy is the most commonly used treatment modality. Doses between 20 to 40 Gy are usually delivered allowing a good symptomatic control, especially for pain relief^{27,68,87,115,135}, compressive symptomatology^{83,87} or intractable vomiting due to seeding to fourth ventricle⁸¹. Although focal LMS from systemic cancers is sometimes treated by stereotactic radiosurgery, its use in GBM LMS is rarely reported^{1,6,60}. The clinical benefit is limited in terms of neurological deficit recovery or survival when administered alone^{27,33,68,84,87,136} and it improves slightly when added to surgery^{27,68,69}. Isolated trials of radiolabeled monoclonal antibodies failed to improve significantly the survival of the LMS patients¹³⁷.

Pharmacological treatment

Multiple chemotherapeutic regimens have been investigated : (i) TMZ alone or combined with BCNU⁷ or CCNU⁵⁵, (ii) Thiotepa alone^{57,58} or combined with Procarbazine^{20,58,64}, (iii) Methotrexate^{6,15,20,57,138}, (iv) Cytarabine^{19,57,129,139,140}, (v) Topotecan or Irinotecan^{15,141,142} and, (vi) Platinum based agents with or without Etoposide^{56,74}. Drug administration was either oral⁷, intravenous^{1,6,11,15,64,143} intrathecal via Ommaya reservoir/lumbar puncture^{6,11,19,21,57,58,139,141,142} or subcutaneous port¹³⁸ or combined^{1,6,7,11,20,110}.

Antiangiogenic drugs (e.g. bevacizumab) alone^{1,44,118,143} or combined with cytotoxic agents (e.g. irinotecan) were used with inconsistent clinical benefit^{15,55,64,85,110,135,144}. Concurrent radio-chemotherapy can be proposed in selected cases eventually in association with antiangiogenic agents^{15,31,55,135}.

Targeted therapy can be considered in selected cases (Table 2) as the MAPK pathway inhibitors (i.e. BRAF and/or MEK inhibitor) in BRAF^{V600E} mutant GBM²³. Dramatic clinical and radiological response were reported with a survival benefit from 1 to 11 months^{23–25,76}. This incites to extensive molecular testing^{23–25}.

As the brain-blood barrier breakdown is low and given the potential resistance mechanism, combined therapy with anti MEK should be considered from the start as it seems associated to longer survival^{23,26}. Radiotherapy can be discussed in order to increase survival while balancing the treatment benefit and its toxicity^{145,146}. Due to the rarity of druggable targets in GBM, this option is available for about 6% of LMS GBM¹¹.

Immunotherapy

Immune checkpoint inhibitors were proposed in cases of high mutational load and with microsatellite instability, alone or in combination with molecular targeted therapies^{23,147}. Nevertheless, there is no clear evidence of their efficacy in LMS^{6,22,85,147}. The use of adoptive cell therapy seems to be of interest. The IL13R α 2-targeted-CAR T cells (with 4-1BB as costimulatory domain and tCD19 as a marker for transduction) had encouraging results with no high-grade therapy-related side effects when used in a LMS of IDH wildtype, MGMT methylated GBM.^{22,148} After repeated intraventricular administration of IL13BB ζ -CAR T cells a clinical and radiologic response was sustained up to 7.5 months²². Other constructs targeting EGFRvIII and HER2 having different costimulatory domains were explored but

their impact on LMS is not reported^{149,150}. However, the difficulty in finding an adequate target, the immunosuppressive microenvironment as well as the consequent toxicities are the limitations of immunotherapy in GBM, including LMS patients¹⁴⁸.

Amongst perspectives, we count gene therapy using engineered mesenchymal stem cells transduced with herpes simplex virus-thymidine kinase gene (MSCtk) followed by systemic Ganciclovir (GCV) in a rat experimental leptomeningeal glioma model that seems to have encouraging results¹⁵¹ and oncolytic viruses tested in transgenic mice inoculated with GBM cells¹⁵². Intrathecal immunoconjugates have also been advocated^{90,153} as well as intratumoral/intrathecal targeted therapy¹⁵⁴.

The completed clinical trials (Table 3) explored the use of multiple intrathecal chemotherapies including topotecan, methotrexate and cytarabine in LMS. Although the safety profile was satisfactory, none of them showed significant improvement of LMS patients' survival^{21,57,140,141}. Noteworthy, the ongoing disease-agnostic clinical trials (Table 4) allow LMS GBM patients inclusion. Nonetheless, their severe neurological impairment and their poor prognosis limit their enrollment.

Following the literature review, a management algorithm is proposed in fig 7.

Survival

LMS in primary malignant CNS tumor implies more aggressive behavior and a worse prognosis. Mean overall survival after diagnosis of treated LMS in high grade gliomas is 4.94 months (2-9 months)^{1,6,7,27,44,60,86,143}. Exceptional OS up to 12 months were reported in cases with nodular LMS where the surgical resection was possible⁸³.

Among treated patients, the median OS was higher regardless chemotherapeutic regimen but the bias of delivering more intensive treatments in patients in better performance status should be taken into account^{1,6,7,11,58,73,139,141}. Among studies, there seems to be a tendency of better survival for patients having received intrathecal chemotherapy (either Depocyt® or thiotepa) with mean survival up to 10 months^{20,30}. A better survival seems associated with antiangiogenic (6-7.6 months mean survivals)^{11,55,143} and molecular targeted therapy when appropriate^{11,24,25}. Nevertheless, all this data needs to be validated in prospective trials.

Despite significant efforts to standardize the response assessment in LMS, this has been proven challenging¹⁵⁵ and it varies according to clinical trial outcome measures. The main criteria for assessing objective response in LMS treatments are the improvement of CSF cytology^{140,141} and radiological decrease of LMS extent^{1,6,7,11,15}.

Up to 50% of LMS patients are treated only by best supportive care and considering the symptoms severity, we need to underline importance of palliative care guidelines in LMS management¹⁵⁶

Prognostic factors

Although the reserved prognosis of LMS is well known, data on the prognostic factors are limited. The interval time from the initial glioma diagnosis to the LMS diagnosis is a potential prognostic factor⁷ as well as Karnofsky Performance Status^{30,82}. Males seem to

have shorter progression free survival though the impact on overall survival does not seem significant³⁰. Noteworthy, the extent of LMS does not seem to have a predictive value¹.

Conclusion

Data on LMS in GBM patients remain scarce while it becomes more common in neuro-oncology clinics. The main problems are the lack of reliable early diagnostic tools and consensual standard of care.

Based on our review of the literature, multimodal treatment of LMS including surgery, radiotherapy, chemotherapy and/or best supportive care is a suitable approach to be discussed during multidisciplinary brain tumor board.

Interestingly, given the advances in glioma therapeutics including molecular targeted therapies and immunotherapies the landscape of LMS treatment is evolving. However, investigations of these innovative treatments remains limited in the setting of LMS and need further studies. Given the dismal prognosis and increasing incidence of this GBM complication, identification of risk factors, biomarkers and efficient therapeutic options in large prospective studies and clinical trials are warranted.

1. Mandel JJ, Yust-Katz S, Cachia D, Wu J, Liu D, de Groot JF, et al. Leptomeningeal dissemination in glioblastoma; an inspection of risk factors, treatment, and outcomes at a single institution. *J Neurooncol*. 2014 Dec;120(3):597–605.
2. Ostrom QT, Gittleman H, Truitt G, Boscia A, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011–2015. *Neuro-Oncol*. 2018 Oct 1;20(suppl_4):iv1–86.
3. Ricard D, Idbaih A, Ducray F, Lahutte M, Hoang-Xuan K, Delattre J-Y. Primary brain tumours in adults. *The Lancet*. 2012 May;379(9830):1984–96.
4. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. *N Engl J Med*. 2005 Mar 10;352(10):987–96.
5. Alatakis S, Malham GM, Thien C. Spinal leptomeningeal metastasis from cerebral glioblastoma multiforme presenting with radicular pain: Case report and literature review. *Surg Neurol*. 2001 Jul 1;56(1):33–7.
6. Noh J-H, Lee MH, Kim WS, Lim DH, Kim ST, Kong D-S, et al. Optimal treatment of leptomeningeal spread in glioblastoma: analysis of risk factors and outcome. *Acta Neurochir (Wien)*. 2015;157(4):569–76.
7. Autran D, Barrie M, Matta M, Monserrat C, Campello C, Petrirena G, et al. Leptomeningeal Gliomatosis: A Single Institution Study of 31 Patients. *Anticancer Res*. 2019 Feb;39(2):1035–41.
8. Yung W-KA, Horten BC, Shapiro WR. Meningeal gliomatosis: A review of 12 cases. *Ann Neurol*. 1980 Dec;8(6):605–8.
9. Krause Molle Z, Gierga K, Turowski B, Steiger H-J, Cornelius JF, Rapp M, et al. 5-ALA-Induced Fluorescence in Leptomeningeal Dissemination of Spinal Malignant Glioma. *World Neurosurg*. 2018 Feb;110:345–8.
10. Onda K, Tanaka R, Takahashi H, Takeda N, Ikuta F. Cerebral glioblastoma with cerebrospinal fluid dissemination: a clinicopathological study of 14 cases examined by complete autopsy. *Neurosurgery*. 1989 Oct;25(4):533–40.
11. Andersen BM, Miranda C, Hatzoglou V, DeAngelis LM, Miller AM. Leptomeningeal metastases in glioma: The Memorial Sloan Kettering Cancer Center experience. *Neurology*. 2019 Apr 24;10.1212/WNL.0000000000007529.
12. Ammerman JM, Kerr PB, Roberti F. Acute tetraplegia and cardiac arrest following high cervical leptomeningeal metastasis of giant cell glioblastoma. *J Clin Neurosci Off J Neurosurg Soc Australas*. 2011 Aug;18(8):1133–5.
13. Jafri NF, Clarke JL, Weinberg V, Barani IJ, Cha S. Relationship of glioblastoma multiforme to the subventricular zone is associated with survival. *Neuro-Oncol*. 2013 Jan;15(1):91–6.
14. Mistry AM, Kelly PD, Gallant J-N, Mummareddy N, Mobley BC, Thompson RC, et al. Comparative Analysis of Subventricular Zone Glioblastoma Contact and Ventricular Entry During Resection in Predicting Dissemination, Hydrocephalus, and Survival. *Neurosurgery*. 2019 May 6;nyz144.

15. Bae J-S, Yang S-H, Yoon W-S, Kang S-G, Hong Y-K, Jeun S-S. The Clinical Features of Spinal Leptomeningeal Dissemination from Malignant Gliomas. *J Korean Neurosurg Soc.* 2011;49(6):334.
16. Falchetti ML, D'Alessandris QG, Pacioni S, et al. Glioblastoma endothelium drives bevacizumab-induced infiltrative growth via modulation of PLXDC1. *Int J Cancer.* 2019;144(6):1331-1344. doi:10.1002/ijc.31983
17. Burger PC, Kleihues P. Cytologic composition of the untreated glioblastoma with implications for evaluation of needle biopsies. *Cancer.* 1989;63(10):2014-2023.
18. Ho C-Y, VandenBussche CJ, Huppman AR, Chaudhry R, Ali SZ. Cytomorphologic and clinicoradiologic analysis of primary nonhematologic central nervous system tumors with positive cerebrospinal fluid. *Cancer Cytopathol.* 2015 Feb;123(2):123–35.
19. Beauchesne P, Blonski M, Brissart H. Response to intrathecal infusions of Depocyt® in secondary diffuse leptomeningeal gliomatosis. A case report. *Vivo Athens Greece.* 2011 Dec;25(6):991–3.
20. Pradat PF, Hoang-Xuan K, Cornu P, Mokhtari K, Martin-Duverneuil N, Poisson M, et al. Treatment of meningeal gliomatosis. *J Neurooncol.* 1999 Sep;44(2):163–8.
21. Levin VA, Chamberlain M, Silver P, Rodriguez L, Prados M. Phase I/II study of intraventricular and intrathecal ACNU for leptomeningeal neoplasia. *Cancer Chemother Pharmacol.* 1989 May;23(5):301–7.
22. Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR, Naranjo A, et al. Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. *N Engl J Med.* 2016 29;375(26):2561–9.
23. Woo PYM, Lam TC, Pu JKS, et al. Regression of BRAFV600E mutant adult glioblastoma after primary combined BRAF-MEK inhibitor targeted therapy: a report of two cases. *Oncotarget.* 2019;10(38):3818-3826. Published 2019 Jun 4
24. Beba Abadal K, Walsh MA, Yachnis AT, Tran DD, Ghiaseddin AP. Eleven Month Progression–Free Survival on Vemurafenib Monotherapy in a Patient With Recurrent and Metastatic *BRAF* V600E–Mutated Glioblastoma WHO Grade 4. *JCO Precis Oncol.* 2017 Jul;(1):1–5.
25. Burger MC, Ronellenfitsch MW, Lorenz NI, Wagner M, Voss M, Capper D, et al. Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease. *Oncol Rep.* 2017 Dec;38(6):3291–6.
26. Kanemaru Y, Natsumeda M, Okada M, Saito R, Kobayashi D, Eda T, et al. Dramatic response of BRAF V600E-mutant epithelioid glioblastoma to combination therapy with BRAF and MEK inhibitor: establishment and xenograft of a cell line to predict clinical efficacy. *Acta Neuropathol Commun.* 2019 Dec;7(1):119.
27. Vertosick FT, Selker RG. Brain Stem and Spinal Metastases of Supratentorial Glioblastoma Multiforme: A Clinical Series. *Neurosurgery.* 1990 Oct 1;27(4):516–22.
28. Arita N, Taneda M, Hayakawa T. Leptomeningeal dissemination of malignant gliomas. Incidence, diagnosis and outcome. *Acta Neurochir (Wien).* 1994 Jun;126(2–4):84–92.

29. Maslehaty H, Cordovi S, Hefti M. Symptomatic spinal metastases of intracranial glioblastoma: clinical characteristics and pathomechanism relating to GFAP expression. *J Neurooncol.* 2011 Jan;101(2):329–33.
30. Dardis C, Milton K, Ashby L, Shapiro W. Leptomeningeal metastases in high-grade adult glioma: development, diagnosis, management, and outcomes in a series of 34 patients. *Front Neurol.* 2014;5:220. Published 2014 Nov 3. doi:10.3389/fneur.2014.00220
31. Lindsay A, Holthouse D, Robbins P, Knuckey N. Spinal leptomeningeal metastases following glioblastoma multiforme treated with radiotherapy. *J Clin Neurosci Off J Neurosurg Soc Australas.* 2002 Nov;9(6):725–8.
32. Roh TH, Park HH, Kang S-G, Moon JH, Kim EH, Hong C-K, et al. Long-term outcomes of concomitant chemoradiotherapy with temozolomide for newly diagnosed glioblastoma patients: A single-center analysis. *Medicine (Baltimore).* 2017 Jul;96(27):e7422.
33. Delattre JY, Walker RW, Rosenblum MK. Leptomeningeal gliomatosis with spinal cord or cauda equina compression: a complication of supratentorial gliomas in adults. *Acta Neurol Scand.* 1989 Feb;79(2):133–9.
34. Bordignon KC, Neto MC, Ramina R, de Meneses MS, Zazula AD, de Almeida LGMP. Patterns of neuroaxis dissemination of gliomas: suggestion of a classification based on magnetic resonance imaging findings. *Surg Neurol.* 2006 May;65(5):472–7; discussion 477.
35. Giese A, Westphal M. Glioma Invasion in the Central Nervous System. *Neurosurgery.* 1996 Aug 1;39(2):235–52.
36. Chen-Zhao X, Aznar-García L. Diagnosis and management of spinal metastasis of primary brain tumours. *AME Case Rep [Internet].* 2018 May 22;2.
37. Wasita B, Kamitani H, Kinoshita Y, Mamun MH, Watanabe T. A rat glioblastoma model with diffuse leptomeningeal gliomatosis induced by intracarotid injection of C6 glioma cells. *Neurol Res.* 2009 Jun;31(5):453–62.
38. Rooprai HK, Rucklidge GJ, Panou C, Pilkington GJ. The effects of exogenous growth factors on matrix metalloproteinase secretion by human brain tumour cells. *Br J Cancer.* 2000 Jan;82(1):52–5.
39. Enam SA, Klaus E. Role of Extracellular Matrix in Tumor Invasion: Migration of Glioma Cells Along Fibronectin-Positive Mesenchymal Cell Processes. *Neurosurgery.* 1998 Mar 1;42(3):599–608.
40. Zhang H, Kelly G, Zerillo C, Jaworski DM, Hockfield S. Expression of a cleaved brain-specific extracellular matrix protein mediates glioma cell invasion *In vivo.* *J Neurosci Off J Soc Neurosci.* 1998 Apr 1;18(7):2370–6.
41. Velásquez C, Mansouri S, Mora C, Nassiri F, Suppiah S, Martino J, et al. Molecular and Clinical Insights into the Invasive Capacity of Glioblastoma Cells. *J Oncol.* 2019 Jul 29;2019:1–16.
42. Pullen N, Pickford A, Perry M, Jaworski D, Loveson K, Arthur D, et al. Current insights into matrix metalloproteinases and glioma progression: transcending the degradation boundary. *Met Med.* 2018 Sep;Volume 5:13–30.

43. Paulus W, Tonn JC. Basement membrane invasion of glioma cells mediated by integrin receptors. *J Neurosurg*. 1994 Mar;515–9.
44. Ruff MW, Kizilbash SH. Glioblastoma with bilateral extraocular muscle infiltration preceded by evidence of vascular tropism. *J Clin Neurosci Off J Neurosurg Soc Australas*. 2019 Mar;61:277–8.
45. Roos A, Ding Z, Loftus JC, Tran NL. Molecular and Microenvironmental Determinants of Glioma Stem-Like Cell Survival and Invasion. *Front Oncol*. 2017 Jun 16;7:120.
46. de Groot JF, Fuller G, Kumar AJ, Piao Y, Eterovic K, Ji Y, et al. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. *Neuro-Oncol*. 2010 Mar 1;12(3):233–42.
47. Otani Y, Ichikawa T, Kurozumi K, Inoue S, Ishida J, Oka T, et al. Fibroblast growth factor 13 regulates glioma cell invasion and is important for bevacizumab-induced glioma invasion. *Oncogene*. 2018 08;37(6):777–86.
48. Seiz M, Nölte I, Pechlivanis I, Freyschlag CF, Schmieder K, Vajkoczy P, et al. Far-distant metastases along the CSF pathway of glioblastoma multiforme during continuous low-dose chemotherapy with temozolomide and celecoxib. *Neurosurg Rev*. 2010 Jul;33(3):375–81.
49. Yamamoto Y, Tamura R, Tanaka T, Ohara K, Tokuda Y, Miyake K, et al. Paradoxical findings of tumor vascularity and oxygenation in recurrent glioblastomas refractory to bevacizumab. *Oncotarget [Internet]*. 2017 Nov 28;8(61).
50. Tamura R, Tanaka T, Miyake K, Tabei Y, Ohara K, Sampetean O, et al. Histopathological investigation of glioblastomas resected under bevacizumab treatment. *Oncotarget*. 2016 Aug 9;7(32):52423–35.
51. Tamura R, Miyoshi H, Sampetean O, Shinozaki M, Morimoto Y, Iwasawa C, et al. Visualization of spatiotemporal dynamics of human glioma stem cell invasion. *Mol Brain*. 2019 Dec;12(1):45.
52. Xiao W, Sohrabi A, Seidlits SK. Integrating the glioblastoma microenvironment into engineered experimental models. *Future Sci OA*. 2017 Aug;3(3):FSO189.
53. da Hora CC, Schweiger MW, Wurdinger T, Tannous BA. Patient-Derived Glioma Models: From Patients to Dish to Animals. *Cells [Internet]*. 2019 Sep 30;8(10).
54. Shibahara I, Saito R, Osada Y, Kanamori M, Sonoda Y, Kumabe T, et al. Incidence of initial spinal metastasis in glioblastoma patients and the importance of spinal screening using MRI. *J Neurooncol*. 2019 Jan;141(2):337–45.
55. Burger MC, Zeiner PS, Jahnke K, Wagner M, Mittelbronn M, Steinbach JP. Addition of Anti-Angiogenetic Therapy with Bevacizumab to Chemo- and Radiotherapy for Leptomeningeal Metastases in Primary Brain Tumors. *PLoS One*. 2016;11(6):e0155315.
56. Perry A, Miller CR, Gujrati M, Scheithauer BW, Zambrano SC, Jost SC, et al. Malignant Gliomas with Primitive Neuroectodermal Tumor-like Components: A Clinicopathologic and Genetic Study of 53 Cases. *Brain Pathol*. 2009 Jan;19(1):81–90.

57. Chamberlain MC. Combined-modality treatment of leptomeningeal gliomatosis. *Neurosurgery*. 2003 Feb;52(2):324–9; discussion 330.
58. Witham TF, Fukui MB, Meltzer CC, Burns R, Kondziolka D, Bozik ME. Survival of patients with high grade glioma treated with intrathecal thiotriethylenephosphoramidate for ependymal or leptomeningeal gliomatosis. :7.
59. Amini A, Schmidt RH, Salzman KL, Chin SS, Couldwell WT. Glioblastoma multiforme of the pineal region. *J Neurooncol*. 2006 Sep;79(3):307–14.
60. Endo H, Kumabe T, Jokura H, Shirane R, Ariga H, Takai Y, et al. Leptomeningeal dissemination of cerebellar malignant astrocytomas. *J Neurooncol*. 2003 Jun;63(2):191–9.
61. Pande S, Pavithran K. Drop metastases to the spinal cord from infratentorial glioblastoma multiforme in post-temozolomide era. *J Cancer Res Ther*. 2015;11(4):1039.
62. Picart T, Barritault M, Berthillier J, Meyronet D, Vasiljevic A, Frappaz D, et al. Characteristics of cerebellar glioblastomas in adults. *J Neurooncol*. 2018 Feb;136(3):555–63.
63. Tsung AJ, Prabhu SS, Lei X, Chern JJ, Benjamin Bekele N, Shonka NA. Cerebellar glioblastoma: a retrospective review of 21 patients at a single institution. *J Neurooncol*. 2011 Dec;105(3):555–62.
64. Linsenmann T, Monoranu CM, Vince GH, Westermaier T, Hagemann C, Kessler AF, et al. Long-term tumor control of spinal dissemination of cerebellar glioblastoma multiforme by combined adjuvant bevacizumab antibody therapy: a case report. *BMC Res Notes*. 2014 Aug 7;7:496.
65. Chan DTM, Hsieh SYP, Kam MKM, Cheung TCY, Ng SCP, Poon WS. Pattern of recurrence and factors associated with cerebrospinal fluid dissemination of glioblastoma in Chinese patients. *Surg Neurol Int*. 2016;7:92.
66. Nunn A, Polyzoidis S, Piechowski-Jozwiak B, Brazil L, Ashkan K. Primary glioblastoma multiforme of the conus medullaris with leptomeningeal metastasis. *J Neurol Sci*. 2017 15;381:315–7.
67. Begemann M, Tsiouris AJ, Malkin MG. Leptomeningeal and ependymal invasion by glioblastoma multiforme. *Neurology*. 2004 Aug 10;63(3):E8.
68. Khan MB, Riaz M, Bari ME. Is surgical spinal decompression for supratentorial GBM symptomatic drop down metastasis warranted? A case report and review of literature. *Surg Neurol Int*. 2014;5:40.
69. Tinchon A, Oberndorfer S, Marosi C, Rudà R, Sax C, Calabek B, et al. Malignant spinal cord compression in cerebral glioblastoma multiforme: a multicenter case series and review of the literature. *J Neurooncol*. 2012 Nov;110(2):221–6.
70. Toyooka T, Miyazawa T, Fukui S, Otani N, Nawashiro H, Shima K. Central neurogenic hyperventilation in a conscious man with CSF dissemination from a pineal glioblastoma. *J Clin Neurosci*. 2005 Sep;12(7):834–7.

71. Witoonpanich P, Bamrungrak K, Jinawath A, Wongwaisayawan S, Phudhichareonrat S, Witoonpanich R. Glioblastoma multiforme at the corpus callosum with spinal leptomeningeal metastasis. *Clin Neurol Neurosurg*. 2011 Jun;113(5):407–10.
72. Fischer CM, Neidert MC, Péus D, Ulrich NH, Regli L, Krayenbühl N, et al. Hydrocephalus after resection and adjuvant radiochemotherapy in patients with glioblastoma. *Clin Neurol Neurosurg*. 2014 May;120:27–31.
73. Bae JY, Choi BO, SunWoo IN, Kim DI, Cho SH, Kim TS. Diffuse cerebrospinal gliomatosis with extensive leptomeningeal spread. *Yonsei Med J*. 2000 Aug;41(4):517–21.
74. Prelaj, A., Rebuzzi, S. E., Caffarena, G., et al. "Therapeutic approach in glioblastoma multiforme with primitive neuroectodermal tumor components: Case report and review of the literature". *Oncology Letters* 15, no. 5 (2018): 6641-6647. <https://doi.org/10.3892/ol.2018.8102>
75. Onuma K, Ishikawa E, Matsuda M, Hirata K, Osuka S, Yamamoto T, et al. Clinical characteristics and neuroimaging findings in 12 cases of recurrent glioblastoma with communicating hydrocephalus. *Neurol Med Chir (Tokyo)*. 2013;53(7):474–81.
76. Leaver KE, Zhang N, Ziskin JL, Vogel H, Recht L, Thomas RP. Response of metastatic glioma to vemurafenib. *Neuro-Oncol Pract*. 2016 Dec;3(4):268–71.
77. Zima LA, Tulpule S, Samson K, Shonka N. Seizure prevalence, contributing factors, and prognostic factors in patients with leptomeningeal disease. *J Neurol Sci*. 2019 Aug;403:19–23.
78. Trivedi RA, Nichols P, Coley S, Cadoux-Hudson TA, Donaghy M. Leptomeningeal glioblastoma presenting with multiple cranial neuropathies and confusion. *Clin Neurol Neurosurg*. 2000 Dec;102(4):223–6.
79. Faivre G, Pentsova E, Demopoulos A, Taillibert S, Rosenblum M, Omuro A. Clinical Reasoning: Worsening neurologic symptoms in a brain tumor patient. *Neurology*. 2015 Aug 18;85(7):e57-61.
80. Goel A, Shah A, Redhu R, Nadkarni T. Supratentorial glioblastoma multiforme with spinal metastases. *J Craniovertebral Junction Spine*. 2010;1(2):126.
81. Cohen ZR, Hassenbusch SJ, Maor MH, Pfeffer RM, Ram Z. Intractable vomiting from glioblastoma metastatic to the fourth ventricle: Three case studies. 2002;5.
82. Montes de Oca Delgado M, Cacho Díaz B, Santos Zambrano J, Guerrero Juárez V, López Martínez MS, Castro Martínez E, et al. The Comparative Treatment of Intraventricular Chemotherapy by Ommaya Reservoir vs. Lumbar Puncture in Patients With Leptomeningeal Carcinomatosis. *Front Oncol*. 2018;8:509.
83. Amitendu S, Mak SKD, Ling JM, Ng WH. A single institution experience of the incidence of extracranial metastasis in glioma. *J Clin Neurosci*. 2012 Nov;19(11):1511–5.
84. Hübner F, Braun V, Richter HP. Case reports of symptomatic metastases in four patients with primary intracranial gliomas. *Acta Neurochir (Wien)*. 2001;143(1):25–9.

85. Schwartz C, Romagna A, Machegger L, Weiss L, Huemer F, Fastner G, et al. Extensive Leptomeningeal Intracranial and Spinal Metastases in a Patient with a Supratentorial Glioblastoma Multiforme, IDH-Wildtype. *World Neurosurg.* 2018 Dec;120:442–7.
86. Saito R, Kumabe T, Jokura H, Shirane R, Yoshimoto T. Symptomatic spinal dissemination of malignant astrocytoma. *J Neurooncol.* 2003 Feb;61(3):227–35.
87. Karaca M, Andrieu MN, Hicsonmez A, Guney Y, Kurtman C. Cases of glioblastoma multiforme metastasizing to spinal cord. *Neurol India.* 2006 Dec;54(4):428–30.
88. Kuo L-T, Tsai S-Y, Yang C-Y, Lin L-W. Meningeal seeding from glioblastoma multiforme treated with radiotherapy and temozolomide. *Asian J Surg.* 2017 Jan;40(1):61–5.
89. Grabb PA, Albright AL, Pang D. Dissemination of supratentorial malignant gliomas via the cerebrospinal fluid in children. *Neurosurgery.* 1992 Jan;30(1):64–71.
90. Lin L, Innerfield CE, Cuccurullo SJ. Symptomatic spinal leptomeningeal metastasis from intracranial glioblastoma multiforme. *Am J Phys Med Rehabil.* 2014 Sep;93(9):838–9.
91. Inamasu J, Nakamura Y, Saito R, Kuroshima Y, Mayanagi K, Orii M, et al. Postoperative communicating hydrocephalus in patients with supratentorial malignant glioma. *Clin Neurol Neurosurg.* 2003 Dec;106(1):9–15.
92. Matsuda M, Kohzuki H, Ishikawa E, Yamamoto T, Akutsu H, Takano S, et al. Prognostic analysis of patients who underwent gross total resection of newly diagnosed glioblastoma. *J Clin Neurosci Off J Neurosurg Soc Australas.* 2018 Apr;50:172–6.
93. Sonoda Y, Saito R, Kanamori M, Kumabe T, Uenohara H, Tominaga T. The association of subventricular zone involvement at recurrence with survival after repeat surgery in patients with recurrent glioblastoma. *Neurol Med Chir (Tokyo).* 2014;54(4):302–9.
94. Roelz R, Reinacher P, Jabbarli R, Kraeutle R, Hippchen B, Egger K, et al. Surgical Ventricular Entry is a Key Risk Factor for Leptomeningeal Metastasis of High Grade Gliomas. *Sci Rep.* 2015 Dec 4;5:17758.
95. Mistry AM, Kelly PD, Thompson RC, Chambless LB. Cancer Dissemination, Hydrocephalus, and Survival After Cerebral Ventricular Entry During High-Grade Glioma Surgery: A Meta-Analysis. *Neurosurgery.* 2018;83(6):1119-1127. doi:10.1093/neuros/nyy202
96. Adeberg S, König L, Bostel T, Harrabi S, Welzel T, Debus J, et al. Glioblastoma recurrence patterns after radiation therapy with regard to the subventricular zone. *Int J Radiat Oncol Biol Phys.* 2014 Nov 15;90(4):886–93.
97. Elliott JP, Keles GE, Waite M, Temkin N, Berger MS. Ventricular entry during resection of malignant gliomas: effect on intracranial cerebrospinal fluid tumor dissemination. *J Neurosurg.* 1994 May;80(5):834–9.
98. Adeberg S, Diehl C, Jung CS, Rieken S, Combs SE, Unterberg A, et al. Is a modification of the radiotherapeutic target volume necessary after resection of glioblastomas with opening of the ventricles? *J Neurooncol.* 2016 May;127(3):581–7.

99. Kim H, Lim DH, Kim TG, Lee J-I, Nam D-H, Seol HJ, et al. Leptomeningeal enhancement on preoperative brain MRI in patients with glioblastoma and its clinical impact. *Asia Pac J Clin Oncol*. 2018 Oct;14(5):e366–73.
100. D’Haene N, Coen N, Neugroschl C, Balériaux D, Salmon I. Leptomeningeal dissemination of low-grade intramedullary gliomas: about one case and review. *Clin Neurol Neurosurg*. 2009 May;111(4):390–4.
101. Lam CH, Cosgrove GR, Drislane FW, Sotrel A. Spinal leptomeningeal metastasis from cerebral glioblastoma. Appearance on magnetic resonance imaging. *Surg Neurol*. 1991 May;35(5):377–80.
102. Kato H, Fujimura M, Kumabe T, Ishioka C, Kanamaru R, Yoshimoto T. PTEN gene mutation and high MIB-1 labeling index may contribute to dissemination in patients with glioblastoma. *J Clin Neurosci Off J Neurosurg Soc Australas*. 2004 Jan;11(1):37–41.
103. Broniscer A, Tatevossian RG, Sabin ND, Klimo P, Dalton J, Lee R, et al. Clinical, radiological, histological and molecular characteristics of paediatric epithelioid glioblastoma: Epithelioid glioblastoma in children. *Neuropathol Appl Neurobiol*. 2014 Apr;40(3):327–36.
104. Babu R, Hatef J, McLendon RE, Cummings TJ, Sampson JH, Friedman AH, et al. Clinicopathological characteristics and treatment of rhabdoid glioblastoma. *J Neurosurg*. 2013 Aug;119(2):412–9.
105. Korshunov A, Sycheva R, Golanov A, Pronin I. Gains at the 1p36 chromosomal region are associated with symptomatic leptomeningeal dissemination of supratentorial glioblastomas. *Am J Clin Pathol*. 2007 Apr;127(4):585–90.
106. Izumoto S, Ohnishi T, Kanemura H, Arita N, Maruno M, Moriuchi T, et al. PTEN mutations in malignant gliomas and their relation with meningeal gliomatosis. *J Neurooncol*. 2001 May;53(1):21–6.
107. Tanaka, S., Batchelor, T.T., Iafrate, A.J. et al. PIK3CA activating mutations are associated with more disseminated disease at presentation and earlier recurrence in glioblastoma. *acta neuropathol commun* 7, 66 (2019). <https://doi.org/10.1186/s40478-019-0720-8>
108. Brandes AA, Tosoni A, Franceschi E, Sotti G, Frezza G, Amistà P, et al. Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status. *J Clin Oncol Off J Am Soc Clin Oncol*. 2009 Mar 10;27(8):1275–9.
109. Zhao YH, Wang ZF, Cao CJ, Weng H, Xu CS, Li K, Li JL, Lan J, Zeng XT and Li ZQ (2018) The Clinical Significance of O6-Methylguanine-DNA Methyltransferase Promoter Methylation Status in Adult Patients With Glioblastoma: A Meta-analysis. *Front. Neurol*. 9:127. doi: 10.3389/fneur.2018.00127
110. Okita Y, Nonaka M, Umehara T, Kanemura Y, Kodama Y, Mano M, et al. Efficacy of temozolomide and bevacizumab for the treatment of leptomeningeal dissemination of recurrent glioblastoma: A case report. *Oncol Lett*. 2015 Apr;9(4):1885–8.
111. Ginat DT, Schaefer PW. Imaging guidelines and findings of extracranial glioblastoma. *J Neurooncol*. 2014 May;118(1):9–18.

112. Shah LM, Salzman KL. Imaging of spinal metastatic disease. *Int J Surg Oncol*. 2011;2011:769753. doi:10.1155/2011/769753
113. Singh SK, Agris JM, Leeds NE, Ginsberg LE. Intracranial Leptomeningeal Metastases: Comparison of Depiction at FLAIR and Contrast-enhanced MR Imaging. *Radiology*. 2000 Oct;217(1):50–3.
114. Harris P, Diouf A, Guilbert F, et al. (April 09, 2019) Diagnostic Reliability of Leptomeningeal Disease Using Magnetic Resonance Imaging. *Cureus* 11(4): e4416. doi:10.7759/cureus.4416
115. Lindsay A, Holthouse D, Robbins P, Knuckey N. Spinal leptomeningeal metastases following glioblastoma multiforme treated with radiotherapy. *J Clin Neurosci Off J Neurosurg Soc Australas*. 2002 Nov;9(6):725–8.
116. King N, Hoch MJ, Shu H-KG, Weinberg BD. Glioblastoma with brainstem leptomeningeal pseudoprogression following radiation therapy. *Radiol Case Rep*. 2019 May;14(5):613–7.
117. Lee J, Kim M-S, Kim YZ. Extensive Pachymeningeal Dissemination of Glioblastoma Mimicking Chronic Subdural Hematoma: A Case Report. *Brain Tumor Res Treat*. 2019;7(1):39.
118. Alvarado A, Salacz M, Chamoun R. Malignant glioma-primitive neuroectodermal tumor recurring as PNET-like only subdural collection: Case report. *Surg Neurol Int*. 2017;8(1):243.
119. Intriago B, Danús M, Añaños M, Trampal C, Montero M, Calvo N. 18F-FDG PET detection of spinal leptomeningeal metastases from cerebral glioblastoma multiforme. *Eur J Nucl Med Mol Imaging*. 2011 Jul;38(7):1392.
120. Unterrainer M, Fleischmann DF, Lindner S, Brendel M, Rupprecht R, Tonn JC, et al. Detection of Cerebrospinal Fluid Dissemination of Recurrent Glioblastoma Using TSPO-PET With 18F-GE-180. *Clin Nucl Med*. 2018 Jul;43(7):518–9.
121. Lombardi G, Zustovich F, Farina P, Della Puppa A, Manara R, Cecchin D, et al. Neoplastic Meningitis from Solid Tumors: New Diagnostic and Therapeutic Approaches. *The Oncologist*. 2011 Aug;16(8):1175–88.
122. Miller AM, Shah RH, Pentsova EI, Pourmaleki M, Briggs S, Distefano N, et al. Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid. *Nature*. 2019 Jan 1;565(7741):654–8.
123. Wang J, Bettegowda C. Applications of DNA-Based Liquid Biopsy for Central Nervous System Neoplasms. *J Mol Diagn*. 2017 Jan;19(1):24–34.
124. Seoane J, De Mattos-Arruda L, Le Rhun E, Bardelli A, Weller M. Cerebrospinal fluid cell-free tumour DNA as a liquid biopsy for primary brain tumours and central nervous system metastases. *Ann Oncol*. 2019 Feb 1;30(2):211–8.
125. Boire A, Brandsma D, Brastianos PK, Le Rhun E, Ahluwalia M, Junck L, et al. Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications. *Neuro-Oncol*. 2019 May 6;21(5):571–84.
126. Nevel KS, Wilcox JA, Robell LJ, Umemura Y. The Utility of Liquid Biopsy in Central Nervous System Malignancies. *Curr Oncol Rep*. 2018 Aug;20(8):60.

127. Heitzer E, Haque IS, Roberts CES, Speicher MR. Current and future perspectives of liquid biopsies in genomics-driven oncology. *Nat Rev Genet.* 2019 Feb;20(2):71–88.
128. Nayak L, Fleisher M, Gonzalez-Espinoza R, Lin O, Panageas K, Reiner A, et al. Rare cell capture technology for the diagnosis of leptomeningeal metastasis in solid tumors. *Neurology.* 2013 Apr 23;80(17):1598–605.
129. Zhao K-H, Zhang C, Bai Y, Li Y, Kang X, Chen J-X, et al. Antiglioma effects of cytarabine on leptomeningeal metastasis of high-grade glioma by targeting the PI3K/Akt/mTOR pathway. *Drug Des Devel Ther.* 2017;11:1905–15.
130. Saito R, Kumabe T, Jokura H, Yoshimoto T. Fatal hemorrhage after radiochemotherapy for leptomeningeal dissemination of glioma: report of two cases. *Surg Neurol.* 2002 Jan;57(1):46–8.
131. Castro BA, Imber BS, Chen R, McDermott MW, Aghi MK. Ventriculoperitoneal Shunting for Glioblastoma: Risk Factors, Indications, and Efficacy. *Neurosurgery.* 2017 Mar;80(3):421–30.
132. Woo PYM, Zhuang JTF, Ho JMK, Seto A, Wong H-T, Chan K-Y. Intraventricular urokinase to treat a blocked ventriculoperitoneal shunt in a glioblastoma patient with leptomeningeal spread. *Acta Neurochir (Wien).* 2018 May;160(5):1073–7.
133. de la Fuente MI, DeAngelis LM. The role of ventriculoperitoneal shunting in patients with supratentorial glioma. *Ann Clin Transl Neurol.* 2014 Jan;1(1):45–8.
134. Hong B, Polemikos M, Heissler HE, Hartmann C, Nakamura M, Krauss JK. Challenges in cerebrospinal fluid shunting in patients with glioblastoma. *Fluids Barriers CNS.* 2018 Jun 4;15(1):16.
135. Fiorentino A, Caivano R, Chiumento C, Cozzolino M, Fusco V. Radiotherapy and bevacizumab for intramedullary and leptomeningeal metastatic glioblastoma: a case report and review of the literature. *Int J Neurosci.* 2012 Nov;122(11):691–4.
136. Scocciati S, Detti B, Meattini I, Iannalfi A, Sardaro A, Leonulli BG, et al. Symptomatic leptomeningeal and intramedullary metastases from intracranial glioblastoma multiforme: a case report. *Tumori.* 2008 Dec;94(6):877–81.
137. Brown MT, Coleman RE, Friedman AH, Friedman HS, McLendon RE, Reiman R, et al. Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results. *Clin Cancer Res Off J Am Assoc Cancer Res.* 1996 Jun;2(6):963–72.
138. Shinoura N, Tabei Y, Yamada R, Saito K, Takahashi M. Continuous intrathecal treatment with methotrexate via subcutaneous port: implication for leptomeningeal dissemination of malignant tumors. *J Neurooncol.* 2008 May;87(3):309–16.
139. Scott BJ, van Vugt VA, Rush T, Brown T, Chen CC, Carter BS, et al. Concurrent intrathecal methotrexate and liposomal cytarabine for leptomeningeal metastasis from solid tumors: a retrospective cohort study. *J Neurooncol.* 2014 Sep;119(2):361–8.
140. Glantz MJ, Jaeckle KA, Chamberlain MC, Phuphanich S, Recht L, Swinnen LJ, et al. A Randomized Controlled Trial Comparing Intrathecal Sustained-release Cytarabine (DepoCyt) to

- Intrathecal Methotrexate in Patients with Neoplastic Meningitis from Solid Tumors. *Clin Cancer Res.* 1999 Nov 1;5(11):3394–402.
141. Gammon DC, Bhatt MS, Tran L, Van Horn A, Benvenuti M, Glantz MJ. Intrathecal topotecan in adult patients with neoplastic meningitis. *Am J Health-Syst Pharm AJHP Off J Am Soc Health-Syst Pharm.* 2006 Nov 1;63(21):2083–6.
 142. Gil MJ, de Las Peñas R, Reynés G, Balañá C, Pérez-Segura P, García-Velasco A, et al. Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO). *Anticancer Drugs.* 2012 Jul;23(6):659–65.
 143. Matsuda M, Ishikawa E, Yamamoto T, Akutsu H, Takano S, Matsumura A. Efficacy of bevacizumab therapy in recurrent malignant gliomas in relation to the prior recurrence pattern or tumor location. *J Clin Neurosci Off J Neurosurg Soc Australas.* 2017 Jun;40:115–9.
 144. Kaloshi G, Roji A, Seferi A, Cakani B, Bushati T, Roci E, et al. Spinal Dissemination of Intracranial Glioblastoma in Bevacizumab Era: a Potential Bevacizumab-induced Mechanism. *Acta Inform Medica AIM J Soc Med Inform Bosnia Herzeg Cas Drustva Za Med Inform BiH.* 2014 Apr;22(2):142–4.
 145. Dasgupta T, Olow AK, Yang X, Hashizume R, Nicolaidis TP, Tom M, et al. Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma. *J Neurooncol.* 2016 Feb;126(3):385–93.
 146. Behling, F.; Schittenhelm, J. Oncogenic BRAF Alterations and Their Role in Brain Tumors. *Cancers* 2019, 11, 794.
 147. Johanns TM, Miller CA, Dorward IG, Tsien C, Chang E, Perry A, et al. Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy. *Cancer Discov.* 2016 Nov 1;6(11):1230–6.
 148. Brown MP, Ebert LM, Gargett T. Clinical chimeric antigen receptor-T cell therapy: a new and promising treatment modality for glioblastoma. *Clin Transl Immunology.* 2019;8(5):e1050. Published 2019 May 20. doi:10.1002/cti2.1050
 149. Ahmed N, Brawley V, Hegde M, Bielasowicz K, Kalra M, Landi D, et al. HER2-Specific Chimeric Antigen Receptor–Modified Virus-Specific T Cells for Progressive Glioblastoma. *JAMA Oncol.* 2017 Aug 1;3(8):1094–101.
 150. O'Rourke DM, Nasrallah MP, Desai A, et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. *Sci Transl Med.* 2017;9(399):eaaa0984. doi:10.1126/scitranslmed.aaa0984
 151. Gu C, Li S, Tokuyama T, Yokota N, Namba H. Therapeutic effect of genetically engineered mesenchymal stem cells in rat experimental leptomeningeal glioma model. *Cancer Lett.* 2010 May 28;291(2):256–62.
 152. Ochiai H. Targeted Therapy for Glioblastoma Multiforme Neoplastic Meningitis with Intrathecal Delivery of an Oncolytic Recombinant Poliovirus. *Clin Cancer Res.* 2006 Feb 15;12(4):1349–54.

153. Johnson VG, Wrobel C, Wilson D, Zovickian J, Greenfield L, Oldfield EH, et al. Improved tumor-specific immunotoxins in the treatment of CNS and leptomeningeal neoplasia. *J Neurosurg.* 1989 Feb;70(2):240–8.
154. Asano K, Ohkuma H. Epithelial Growth Factor Receptor Tyrosine Kinase Inhibitor Prevents Infiltration and Cerebrospinal Fluid Dissemination in Malignant Glioma: An Experimental Study: *Neurosurgery.* 2011 Aug;69(2):399–411.
155. Le Rhun E, Devos P, Boulanger T, Smits M, Brandsma D, Rudà R, et al. The RANO Leptomeningeal Metastasis Group proposal to assess response to treatment: lack of feasibility and clinical utility and a revised proposal. *Neuro-Oncol.* 2019 06;21(5):648–58.
156. Pace A, Dirven L, Koekkoek JAF, Golla H, Fleming J, Rudà R, et al. European Association for Neuro-Oncology (EANO) guidelines for palliative care in adults with glioma. *Lancet Oncol.* 2017;18(6):e330–40.